London School of Hygiene and Tropical Medicine
London, WC1E 7HT, United Kingdom
NCT Number: NCT01452997
The purpose of this study is to evaluate two separate antiinflammatory products for the relief of symptoms through suppression of the immunological and inflammatory response following a mosquito bite. The investigators have selected ibuprofen gel as a NSAI formulation and 0.05% Clobetasone butyrate as a steroid cream with their appropriate physical matched placebo products.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
London, WC1E 7HT, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
18 to 65 years of age (inclusive). Caucasian (white or pale skin) Good health as determined by medical history and physical examination Females of child bearing potential must confirm they are not pregnant at the study start and agree not to become pregnant throughout the duration of the study.
History of the following triad of symptoms following a previous mosquito bite: weal, flare, and pruritus as immediate reaction to mosquito bites at least once in the past (= mosquito bite sensitive stages III or IV).
Willingness to attend for all study procedures at designated intervals. Willingness to provide full consent to the study
Exclusion criteria
Abnormalities of the skin on the forearms (including sunburn) that might interfere with the study results, as determined by the investigator/clinician during physical inspection.
History of clinically significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, metabolic, or other disease deemed clinically significant by investigator / clinician Use of prohibited therapies (including cosmetics on either forearm) as specified in Section 6.3.3 of the Clinical Trial Protocol (use of systemic or local antihistamines, steroids, or NSAIDs during or within 2 weeks prior to planned date of first study procedure); use of any medication considered to have an influence on the outcome of the study.
Any acute illness within the 7 days prior to planned date of first study procedure which might interfere with the study results (as determined by the investigator/clinician from medical history).
History of malignancy within 5 years of the planned date of the first study procedure Neurological or psychiatric disease, or drug or alcohol abuse which would interfere with the subject's completion of the protocol assignments.
Participated in research involving an investigational drug within 3 months of the planned date of first study procedure.
History of known anaphylactic hypersensitivity to mosquitoes bites, bee or wasp stings.
History of allergic reaction to any of the topical agents used in the study or any of their components.
History of allergy to latex or other rubber material Women who are pregnant or breastfeeding
Ibuprofen 5% gel
Other names: Fenbid gel
Steroid intervention with 0.05% w/w clobetasone butyrate.
Time frame: 90 minutes
The statistical difference between active and placebo agent on bite reaction measured as size of wheal, flare in mm and itching measured on a visual scale recorded by the subject.ct.
Time frame: 90 minutes
Subjective record of pain and itching recorded on a visual scale
London School of Hygiene and Tropical Medicine
Other
Evaluation of Topical Ibuprofen and Steroid in the Reduction of Local Reactions and Symptoms From an Aedes Aegypti Mosquito Bite
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07686159
Mosquito Bite, Mosquito Repellent
Dhaka, Dhaka Division, Bangladesh
View Trial DetailsNCT01075256
Bites and Stings, Chemically-Induced Disorders
Fort Wayne, Indiana, United States
View Trial DetailsNCT00114894
Bites and Stings, Chemically-Induced Disorders
Key West, Florida, United States
View Trial DetailsNCT00852943
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bethesda, Maryland, United States
View Trial Details